Background
Materials and methods
Patients and procedures
Characteristic | n. | % |
---|---|---|
No. of patients | 76 | |
Male | 54 | 70 |
Female | 22 | 30 |
68 | - | |
Range, years | 38-88 | - |
Primary tumor | ||
Colorectal | 29 | 38 |
NSCLC | 18 | 24 |
Sarcoma | 6 | 8 |
Genitourinary | 8 | 10.5 |
Other | 15 | 19.5 |
Other metastatic sites | ||
Bone | 2 | 2.6 |
Visceral | 4 | 5.2 |
Time since diagnosis (mos) | ||
Median | 48 | - |
Range | 10-180 | - |
Treatment | No. | % |
Lung lesions treated | 118 | |
No. of lung lesions (per patient) | ||
49 | 64 | |
18 | 24 | |
9 | 12 | |
Dose prescription (per lesion) | ||
48 Gy/12 Gy fraction | 95 | 80.5 |
60 Gy/20 Gy fraction | 7 | 6 |
60 Gy/7.5 Gy fraction | 16 | 13.5 |
Treatment
Outcome evaluation
Statistical analysis
Results
Dosimetric data
Parameter | Objective | Mean ± SD | Range |
---|---|---|---|
CTV
| |||
Volume = 13.9 ± 25.8 cm3 Range = [.5 – 183.6] cm3 | |||
Mean [Gy]
| 100% | 101.4 ± 1.7 | [98.4 - 106.4] |
V
98%
[%]
| >98% | 98.1 ± 3.4 | [80.3 - 100.0] |
D
99%
[Gy]
| Maximize | 98.25 ± 1.7 | [94.3 - 103.2] |
D
1%
[Gy]
| Minimize | 104.3 ± 2.1 | [99.8 - 112.9] |
PTV
| |||
Volume = 42.3 ± 51.2 cm3 Range = [2.5 – 333.1] cm3 | |||
Mean [Gy]
| 100% | 100.3 ± 0.3 | [96.8 - 104.9] |
V
95%
[%]
| >95% | 96.7 ± 1.9 | [90.2 - 99.9] |
D
99%
[Gy]
| Maximize | 93.1 ± 2.0 | [89.5 - 96.6] |
D
1%
[Gy]
| Minimize | 104.8 ± 1.8 | [101.9 - 112.9] |
Lungs
| |||
Mean [Gy]
| <4 Gy | 3.7 ± 3.8 | [0.5 - 16.8] |
V
5Gy
[%]
| <30% | 17.9 ± 18.8 | [0.1 - 78.2] |
V
10Gy
[%]
| <20% | 11.2 ± 14.2 | [0.1 - 65.8] |
V
20Gy
[%]
| <10% | 5.2 ± 7.4 | [0.0 - 34.6] |
Spinal cord
| |||
D
1%
[Gy]
| <20 Gy | 10.2 ± 5.6 | [2.2 - 21.7] |
Heart
| |||
D
1%
[Gy]
| <30 Gy | 11.3 ± 10.9 | [0.5 - 28.6] |
Esophagus
| |||
D
1%
[Gy]
| <30 Gy | 16.3 ± 11.5 | [5.1 - 36.1] |
Local control
Toxicity
Survival
Discussion
Study | No patients | Median dose/no fractions | Median FU mos (range) | Local control rate | Overall survival | Toxicity |
---|---|---|---|---|---|---|
Okunieff et al [13] | 50 | 50 Gy/10 | 18.7 (3.7-60.9) | 3-yr 91% | 2-yr 50% | G2 6.1% |
48 Gy/6 | G3 2% | |||||
57 Gy/3 | ||||||
Norihisa et al [15] | 34 | 48 Gy/4 | 27 (10-80) | 2-yr 90% | 2-yr 84% | G2 12% |
60 Gy/5 | G3 3% | |||||
Le et al [14] | 32 | 15 Gy/1 | - | 1-yr 54% | G2-G3 4 | |
20 Gy/1 | 1-yr 54% | G5 3 | ||||
25 Gy/1 | 1-yr 91% | Dose ≥ 25 Gy | ||||
30 Gy/1 | 1-yr 91% | |||||
2-yr 67% | ||||||
Salama et al [16] | 61 | 24 Gy/3 | 20.9 (3-60.5) | 1-yr 67.2% | 2-yr 56.7% | G3 3 |
48 Gy/3 | 2-yr 52.7% | |||||
Rushoven et al [17] | 38 | 60 Gy/3 | 15.4 (6-48) | 2-yr 96% | 2-yr 39% | G3 3 (8%) |
Ricardi et al [18] | 61 | 45 Gy/3 | 20.4 (3-77) | 2-yr 89% | 2-yr 66.5% | G3 1 (1.6%) |
26 Gy/1 |